Skip to main content
OPTISCAN IMAGING LIMITED logo

OPTISCAN IMAGING LIMITED — Investor Relations & Filings

Ticker · OIL ISIN · AU000000OIL4 ASX Manufacturing
Open in API
Filings indexed 889 across all filing types
Latest filing 2026-05-24 Director's Dealing
Country AU Australia
Listing ASX OIL

About OPTISCAN IMAGING LIMITED

https://www.optiscan.com

Optiscan Imaging Limited specializes in the development and commercialization of endomicroscopic imaging technologies. The company’s core expertise lies in confocal laser endomicroscopy, which enables real-time, high-resolution digital pathology at the cellular level. Its proprietary technology allows clinicians and researchers to perform virtual biopsies, visualizing tissue architecture in vivo without the need for physical tissue removal. Key products include the ViewnVivo system for preclinical research and the Five2 platform designed for clinical applications, particularly in the early detection and management of cancer. These systems are utilized across various medical fields, including oncology, gastroenterology, and oral health, to improve diagnostic accuracy and surgical precision. By integrating advanced optics and software, the company provides tools for immediate intraoperative decision-making and longitudinal biological studies.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 3 pages 330.2KB
Director's Dealing Classification · 92% confidence The document is an ASX Appendix 3Y “Change of Director’s Interest Notice” under listing rule 3.19A.2, detailing the acquisition and disposal of securities by a company director. This is a director insider share transaction report. Therefore, it falls under the “Director’s Dealing” category (Code: DIRS).
2026-05-24 English
Optiscan Receives $1.69m R&D Tax Refund 2 pages 135.7KB
Regulatory Filings Classification · 78% confidence The document is a routine ASX market announcement disclosing that Optiscan has received its FY25 R&D tax refund. It is not an earnings release or formal financial report, nor does it attach or publish any substantive report. It is not about a change in management, share issuance, dividend, or detailed financing transaction. Therefore it falls under general regulatory announcements that do not fit other categories and should be classified as Regulatory Filings (RNS).
2026-05-19 English
Quarterly Activities/Appendix 4C Cash Flow Report 14 pages 589.8KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 30 April 2026 from Optiscan Imaging Ltd. It is titled 'APPENDIX 4C QUARTERLY ACTIVITIES & CASHFLOW REPORT QUARTER ENDED 31 MARCH 2026'. The content includes detailed quarterly operational updates, clinical study progress, regulatory submission status, product development, and commercialisation efforts. It contains substantive financial data such as R&D expenditure and cashflow report references. The document is about a quarterly period ending 31 March 2026 and provides comprehensive financial and operational information for that quarter. This matches the definition of an Interim / Quarterly Report (IR), which must contain actual financial statements or substantive financial data and analysis for a period shorter than a full fiscal year. The document is not merely an announcement of a report but contains detailed quarterly data and narrative. Therefore, the correct classification is IR with high confidence.
2026-04-29 English
Optiscan Submits InSpecta FDA Dossier 6 pages 627.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 31 March 2026 from Optiscan Imaging Ltd regarding the submission of a regulatory dossier to the U.S. FDA for their InSpecta® veterinary device. The content focuses on the regulatory submission milestone, its significance, and the commercial and strategic implications. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about a regulatory filing event rather than a financial report or detailed regulatory filing like an audit or annual report. It is not a certification or officer attestation. The document is longer than 5,000 characters and contains substantive information about the regulatory submission. This fits best under the category of a Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit into more specific categories like Capital/Financing Update or Legal Proceedings. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-03-30 English
Change in substantial holding 2 pages 388.3KB
Regulatory Filings
2026-03-16 English
Appendix 4D 3 pages 226.8KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Optiscan Imaging Limited Appendix 4D Half-year report' and covers the half-year period ended 31 December 2025. It contains detailed financial performance data, including revenues, losses, expenses, net assets, and cash flows for the half-year period. It also references an audit review and includes financial metrics such as net tangible assets per security. The document is over 5,000 characters and contains substantive financial data and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). Although it references an audit review, the audit report is attached separately and this document itself is the half-year financial report. Therefore, the correct classification is IR with high confidence.
2026-02-24 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.